Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease

Официальное название

The Impact of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease: a Multicenter, Randomized, Single-blind, Blank-controlled Clinical Study

Обзор

The goal of this clinical trial is to evaluate the effect of supplementing Bacillus subtilis compared to the control group on the efficacy of Infliximab in patients with Crohn's disease, and to summarize the role of supplementing Bacillus subtilis in the treatment of CD patients. Participants will be randomized into two groups: the Bacillus subtilis supplementation group and the control group. The patients in the Bacillus subtilis supplementation group received oral Bacillus subtilis capsules for 12 weeks. The control group did not receive additional intervention. Follow up once a week, and after the study, patients will come to the hospital to finish the evaluation indicators.

Подробное описание

The goal of this clinical trial is to evaluate the effect of supplementing Bacillus subtilis compared to the control group on the efficacy of Infliximab in patients with Crohn's disease, and to summarize the role of supplementing Bacillus subtilis in the treatment of CD patients.

Participants will be randomized into two groups: the Bacillus subtilis supplementation group and the control group. Patients in the Bacillus subtilis supplementation group take oral Bacillus subtilis capsules once a day, one capsule per time, for 12 weeks, each containing 3×10⁹ CFU of Bacillus subtilis. The control group did not receive additional intervention. Follow up once a week, and after the study, patients will come to the hospital to finish the evaluation indicators.

Вмешательства

• Пищевая добавка Bacillus subtilis Capsules
  Bacillus subtilis is a type of probiotic. Studies have found that supplementation with Bacillus subtilis can effectively maintain the remission of inflammatory bowel disease by protecting intestinal integrity, regulating epithelial proliferation, and reshaping the structure and function of the microbiota. Bacillus subtilis capsules are a Bacillus supplement containing 3×10⁹ CFU of Bacillus subtilis per capsule. Patients in the Bacillus subtilis supplementation group take Bacillus subtilis capsu

Первичные конечные точки

• Endoscopic remission rate [Срок оценки: 12 weeks]
• Clinical remission rate [Срок оценки: 12 weeks]

Вторичные конечные точки (1)

• Biomarker target attainment rate [Срок оценки: 12 weeks]

Критерии участия

Критерии включения

• Age ≥ 18 years old, ≤ 75 years old;
• Patients clinically diagnosed with Crohn's disease shall refer to the Chinese Guidelines for the Diagnosis and Treatment of Crohn's Disease (Guangzhou, 2023) for diagnostic criteria;
• Patients receiving treatment with Infliximab;
• The patient is currently in the clinical active stage(CDAI≥150 or SES-CD≥3);
• Agree to participate in this study and sign an informed consent form.

Критерии исключения

Participants who meet any of the following criteria are not eligible for inclusion in this study.

• Patients with ALT or AST exceeding the normal upper limit by more than twice, and TBIL exceeding the normal upper limit by more than twice;
• Patients with creatinine clearance rate less than 60ml/min;
• Patients with severe active infections in the intestines or other areas that require the use of antibiotics or antiviral drugs;
• Patients with intestinal tuberculosis, other chronic intestinal infectious diseases, and intestinal malignant tumors;
• Pregnant and lactating women;
• The fasting blood glucose of patients with diabetes or screening period exceeds 7.0mmol/L or glycosylated hemoglobin exceeds 6.5%;
• Merge patients with severe mental illness, drug use, alcohol abuse, etc. who are unable to cooperate with the study;
• Have participated in any other clinical research within the first month prior to enrollment;
• The researcher determined that any other disease or condition is not suitable for patients participating in this study.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Простое слепое

Основная цель

Лечение

Центры проведения

Китай · 1 центр

• The Third Xiangya Hospital of Central South University — Чанша

Идентификаторы

NCT: NCT07123207 · 2025-IFX-BS-XY3

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗